See more : SurgLine International, Inc. (SGLN) Income Statement Analysis – Financial Results
Complete financial analysis of Gamida Cell Ltd. (GMDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gamida Cell Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mukat Pipes Limited (MUKATPIP.BO) Income Statement Analysis – Financial Results
- Phoenix Media Investment (Holdings) Limited (PXSTF) Income Statement Analysis – Financial Results
- Dream Finders Homes, Inc. (DFH) Income Statement Analysis – Financial Results
- AS PARTNERS CO LTD (160A.T) Income Statement Analysis – Financial Results
- USCorp (USCS) Income Statement Analysis – Financial Results
Gamida Cell Ltd. (GMDA)
About Gamida Cell Ltd.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.48M | 440.00K | 431.00K | 357.00K | 2.14M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.69M | -440.00K | -431.00K | -357.00K | -2.14M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -94.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 22.28M | 42.69M | 50.18M | 41.39M | 31.46M | 22.05M | 15.02M | 19.10M |
| General & Administrative | 44.58M | 19.40M | 16.98M | 12.17M | 12.09M | 11.60M | 4.47M | 4.61M |
| Selling & Marketing | 4.08M | 12.90K | 20.01K | 8.89K | 4.69K | 0.00 | 0.00 | 0.00 |
| SG&A | 48.67M | 19.40M | 16.98M | 12.17M | 12.09M | 11.60M | 4.47M | 4.61M |
| Other Expenses | -395.00K | 12.90M | 20.01M | 8.75M | 4.69M | 195.00K | -2.27M | 1.81M |
| Operating Expenses | 70.95M | 74.99M | 87.17M | 62.30M | 48.25M | 33.64M | 19.49M | 23.71M |
| Cost & Expenses | 74.43M | 74.99M | 87.17M | 62.30M | 48.25M | 33.64M | 19.49M | 23.71M |
| Interest Income | 2.73M | 4.38K | 2.63K | 236.00K | 17.15M | 1.04M | 330.00K | 163.00K |
| Interest Expense | 7.59M | 4.38M | 2.63M | 10.64M | 3.33M | 20.26M | 30.00K | 23.00K |
| Depreciation & Amortization | 2.02M | -149.55M | 431.00K | 2.63M | 19.29M | 269.00K | 162.00K | 124.00K |
| EBITDA | -70.62M | -74.55M | -86.74M | -60.57M | -28.95M | -32.60M | -20.16M | -24.48M |
| EBITDA Ratio | -3,958.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.64M | 74.99M | -87.17M | -62.30M | -48.25M | -33.64M | -19.49M | -23.71M |
| Operating Income Ratio | -4,071.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.65M | -4.38M | -2.63M | -648.00K | 13.82M | -19.22M | 479.00K | 1.04M |
| Income Before Tax | -63.00M | -79.38M | -89.79M | -72.70M | -34.42M | -52.86M | -19.01M | -22.67M |
| Income Before Tax Ratio | -3,531.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.00 | 74.99M | 2.63M | 3.74M | -70.00K | 70.00K | -479.00K | -1.04M |
| Net Income | -63.00M | -154.37M | -92.42M | -76.45M | -34.35M | -52.93M | -19.01M | -22.67M |
| Net Income Ratio | -3,531.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.57 | -2.42 | -1.56 | -1.75 | -1.17 | -10.53 | -1.06 | -1.26 |
| EPS Diluted | -0.57 | -2.42 | -1.56 | -1.75 | -1.16 | -10.53 | -1.06 | -1.26 |
| Weighted Avg Shares Out | 110.05M | 63.83M | 59.25M | 43.73M | 29.46M | 5.03M | 17.97M | 17.97M |
| Weighted Avg Shares Out (Dil) | 110.05M | 63.83M | 59.25M | 43.73M | 29.66M | 5.03M | 17.97M | 17.97M |
Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate...
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today announced encouraging preclinical data on GDA-501, a genetically modified NAM (nicotinamide) Natural...
Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast...
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematological and solid cancers and other serious diseases, today announced an oral presentation of a real-world analysis comparing the effectiveness of...
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that Michele Korfin, Chief Operating Officer and Chief Commercial Officer, will present...
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that Michele Korfin, Chief Operating Officer and Chief Commercial Officer, will present...
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the presentation of new long term follow-up data and health-related quality of...
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the presentation of new long term follow-up data and health-related quality of...
Source: https://incomestatements.info
Category: Stock Reports